NOTCH1 and acute lymphoblastic leukemia: Finally, in a phase I trial including patients with T-ALL and T cell lymphoblastic lymphoma, PF-03084014 treatment achieved a complete response in a heavily pre-treated patient with T-ALL harboring an activating NOTCH1 mutation (L1679P) [192].